⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Official Title: A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients

Study ID: NCT04464174

Study Description

Brief Summary: This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated unresectable locally advanced or metastatic triple-negative breast cancer patients

Detailed Description: Women age ≥ 18 years with triple-negative unresectable locally advanced or MBC that is not amenable to resection with curative intent. Patients must have received at least one, but not more than two, prior chemotherapeutic regimens for treatment of unresectable locally advanced and/or metastatic disease (at least one regimen must have contained a taxane). The number of patients to be included is 54 patients. The primary objective is to evaluate the safety and tolerability of ipatasertib (GDC-0068) in combination with capecitabine, eribulin, or carboplatin plus gemcitabine in patients with unresectable locally advanced or metastatic triple-negative breast cancer

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Champalimaud Clinical Centre - Champalimaud Foundation, Lisboa, , Portugal

Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, , Portugal

Hospital Provincial de Castellón, Castellón De La Plana, Castellón, Spain

Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain

Hospital del Mar, Barcelona, , Spain

Hospital Universitari Dexeus, Barcelona, , Spain

Hospital San Pedro de Alcántara, Cáceres, , Spain

Hospital Universitari Arnau de Vilanova, Lleida, , Spain

Hospital Quiron San Camilo- Ruber Juan Bravo, Madrid, , Spain

Hospital Universitario Ramón y Cajal, Madrid, , Spain

Hospital Universitario Virgen de la Victoria, Málaga, , Spain

Hospital Clínico Universitario de Valencia, Valencia, , Spain

Hospital Arnau de Vilanova, Valencia, , Spain

Hospital Universitario Miguel Servet, Zaragoza, , Spain

Contact Details

Name: Antonio Llombart, MD

Affiliation: MedSIR

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: